Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Trial Profile

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2019

At a glance

  • Drugs Lenvatinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLECT
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 28 Jun 2019 Results published in the British Journal of Cancer
    • 04 Jun 2019 Results assessing safety and efficacy of patients who did not meet inclusion criteria of this study (n=128) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 25 Apr 2019 Planned End Date changed from 31 Mar 2019 to 30 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top